Iovance Biotherapeutics (IOVA) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
29 Oct, 2026Commercial and financial outlook
Amtagvi is the first and only approved treatment for 2L+ advanced melanoma; commercial markets include the U.S., Canada and Australia, while Proleukin is marketed globally.
~2,000 patients treated with commercial and clinical TIL products; ~100 authorized treatment centers, with >95% of addressable patients within 200 miles and >250M covered lives.
FY26 revenue guidance is $410M–$420M; midpoint rose $55M, or ~15%, from prior guidance. 2Q26 revenue was ~$99M, >10% above guidance and up ~66% YoY.
2Q26 gross margin was 56% of cost of sales, excluding D&A; cash was ~$304M as of June 30, 2026, with runway into 2H28.
Clinical evidence and registrational programs
At 5-year follow-up in pooled, heavily pretreated melanoma patients, lifileucel showed 31.4% ORR, 36.5-month mDOR and 19.7% 5-year OS; median follow-up was 57.8 months.
Real-world melanoma data showed 44% ORR and 73% DCR; ORR was 52% with ≤2 prior lines versus 33% with ≥3 prior lines.
Frontline melanoma lifileucel plus pembrolizumab data showed 65.2% ORR, 30.4% CR and 64.7% PFS at 6 and 12 months; median PFS and DOR were not reached at 21.7-month median follow-up.
Phase 3 TILVANCE-301 is testing lifileucel plus pembrolizumab versus pembrolizumab alone in 670 patients; dual primary endpoints are ORR and PFS, with enrollment on track.
In post-treatment nonsquamous mNSCLC, interim lifileucel data showed 25.6% ORR and mDOR not reached at 25.4-month median follow-up; the program has FDA Fast Track Designation.
Platform and pipeline expansion
Centralized Philadelphia manufacturing uses a scaled, FDA-approved commercial TIL process; turnaround is ~31 days and annual capacity exceeds 5,000 patients.
Phase 2 SARATOGA began in 2Q26 for advanced UPS and DDLPS; earlier evaluable data showed 50% ORR, and the registrational study targets patients with 1–3 prior systemic treatments.
In endometrial cancer, the first five evaluable patients had 40% confirmed ORR and 100% DCR; all had pMMR disease and prior chemotherapy and checkpoint inhibitor therapy.
Next-generation programs include PD-1-inactivated TIL IOV-4001, IL-2 supportive therapy IOV-3001 and IL-12-tethered TIL IOV-5001, with clinical studies across solid tumors.
Latest events from Iovance Biotherapeutics
- Lifileucel achieved a 59.1% ORR in the biomarker-enriched mNSCLC subgroup.IOVA
Study update - Record revenue and strong clinical results drive expansion and innovation in TIL therapy.IOVA
H.C. Wainwright 28th Annual Global Investment Conference - Strong sales growth, expanding clinical pipeline, and operational efficiencies support long-term outlook.IOVA
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue surged 66% to $99.3M, margin hit 56%, and cash reserves support ongoing growth.IOVA
Q2 2026 - Strong revenue growth and durable TIL therapy efficacy drive expansion in solid tumor oncology.IOVA
Corporate presentation - All proposals passed; strong growth, robust pipeline, and focus on revenue and margin improvement.IOVA
AGM 2026 - AMTAGVI’s rapid growth and strong clinical data drive expansion, with pivotal trials and new therapies advancing.IOVA
Jefferies Global Healthcare Conference 2026 - Five-year data confirm durable survival and expanding access for one-time TIL cell therapy in melanoma.IOVA
KOL event - Q1 2025 revenue was $49.3M; FY25 guidance is $250–$300M with global expansion underway.IOVA
Q1 2025